Table 1

Adult survival statistics for all trials.

Trial

Concentration (μM)

Mean lifespan (days)

Relative survival (%)

p (Logrank)

n (failed, censor)


Treated

Control


Resveratrol-trimethylether


1

100

9.7

12.16

80%

0.004

61,0

4

20

7.72

11.26

69%

< 0.001

61,0

4

40

7.72

11.26

69%

< 0.001

74,0

4

100

7.18

11.26

64%

< 0.001

70,2

5

5

18.83

18.49

102%

0.91

46,3

5

20

16.41

18.49

89%

0.055

42,3

5

100

15.18

18.49

82%

0.005

37,6

6

20

9.02

15.32

59%

< 0.0001

49,5

6

40

7.98

15.32

52%

< 0.0001

51,0

6

100

7.54

15.32

49%

< 0.0001

52,0


3-OH-5,4'- dimethoxystilbene


1

100

6.34

12.16

52%

< 0.0001

53,0

2

20

11.05

11.05

100%

0.986

47,2

2

40

10.52

11.05

95%

0.234

40,1

6

20

10.38

15.32

68%

< 0.0001

56,0

6

40

7.68

15.32

50%

< 0.0001

54,1

6

100

6.56

15.32

43%

< 0.0001

55,3


Pterostilbene


1

100

9.55

12.16

79%

0.005

69,9

4

20

10.43

11.26

93%

0.336

54,0

4

40

10

11.26

89%

0.035

65,1

4

100

8.07

11.26

72%

< 0.0001

51,1

6

20

13.72

15.32

90%

0.058

55,1

6

40

14.41

15.32

94%

0.142

51,4

6

100

10.98

15.32

72%

< 0.001

51,0


Desoxyrhapontigenin


1

100

10.64

12.16

88%

0.12

61,1

3

100

11.31

15.37

74%

< 0.0001

36,0

3

200

11.61

15.37

76%

< 0.0001

44,1

4

20

10.2

11.26

91%

0.12

74,0

4

40

10.38

11.26

92%

0.11

71,2

4

100

9.44

11.26

84%

0.003

50,0

6

20

14.18

15.32

93%

0.494

54,3

6

40

15.31

15.32

100%

0.48

59,1

6

100

13.63

15.32

89%

0.027

46,9


Pinostilbene


1

100

13.6

12.16

112%

0.062

68,1

2

20

10.04

11.05

91%

0.266

55,0

2

40

11.53

11.05

104%

0.319

42,5

3

100

16.9

15.37

110%

0.448

41,0

3

200

15.23

15.37

99%

0.411

42,5

6

20

14.24

15.32

93%

0.319

56,3

6

40

17.33

15.32

113%

0.085

60,0

6

100

16.24

15.32

106%

0.724

51,2


Resveratrol


1

100

12.18

12.16

100%

0.867

70,3

2

20

11.85

11.05

107%

0.182

48,4

2

40

10.53

11.05

95%

0.924

55,0

3

100

16.64

15.37

108%

0.435

30,4

3

200

17

15.37

111%

0.337

38,0

6

20

14.65

15.32

96%

0.804

54,5

6

40

16.17

15.32

106%

0.501

59,0

6

100

17.55

15.32

115%

0.055

58,0


Piceatannol


2

20

11.72

11.05

106%

0.362

44,0

2

40

11.58

11.05

105%

0.5

37,9

3

100

17.78

15.37

116%

0.094

55,1

3

200

17.5

15.37

114%

0.166

55,1

6

20

13.71

15.32

89%

0.231

50,1

6

40

15.63

15.32

102%

0.75

50,1

6

100

16.6

15.32

108%

0.146

50,1


Wilson et al. BMC Pharmacology 2008 8:15   doi:10.1186/1471-2210-8-15

Open Data